



**INSTITUTE  
FOR EVIDENCE  
BASED HEALTH**

Advancing Knowledge  
Transforming Healthcare

## Pharmacy Services in Europe: Evaluating Trends and Value PART 2: PHARMACY INTERVENTIONS ON COVID-19

### COUNTRY ASSESSMENT

The Institute for Evidence-Based Health (ISBE) is conducting research for the Pharmaceutical Group of the European Union (PGEU) which aims at synthesizing evidence and trends on pharmacy services in Europe. This research also includes a subset on recent pharmacy interventions on COVID-19 in Europe. The purpose of this section of the survey is to collect data for this subset. The results will be made public in due course. We kindly request you to complete the following survey as accurate as you can.

**Country:** \_\_\_\_\_

|  | <b>PHARMACY INTERVENTIONS ON COVID-19</b>  | <b>Provided in most (≥80%) pharmacies (Y/N)</b> | <b>Expanded powers granted to pharmacists through amending regulations (Y/N)</b><br><i>If Y, please provide link or reference</i> | <b>Remunerated by Government / Payer (Y/N)</b><br><i>If Y and available please provide fees and currency</i> | <b>Extra legislation passed by pharmacy regulators in view of covid-19 (Y/N)</b><br><i>If Y, please provide link or reference</i> | <b>Other data sources</b><br><i>Please provide links or references</i> | <b>OBS</b> |
|--|--|---|---|--|---|--|------------|
| <b>PREVENTION: Measures to reduce health risks of COVID-19 pandemic*</b>                           |  |   |   |  |   |  |            |
| <b>1</b>   | Patient information and education on preventive measures                               |   |   |  |   |  |            |
| <b>2</b>   | Protocols in place for disinfection of pharmacy surfaces                               |   |   |  |   |  |            |
| <b>3</b>   | Use of disposable masks by pharmacy staff  |   |   |  |   |  |            |
| <b>4</b>   | Use of other Personal Protective Equipment by pharmacy staff                           |   |   |  |   |  |            |
| <b>5</b>   | Queue management in pharmacy   |   |   |  |   |  |            |
| <b>6</b>   | Floor marking inside pharmacy  |   |   |  |   |  |            |
| <b>7</b>   | Restriction in pharmacy opening hours  |   |   |  |   |  |            |
| <b>8</b>   | Barriers at counters in pharmacies   |   |   |  |   |  |            |
| <b>9</b>   | Temporary suspension of patient care services  |   |   |  |   |  |            |
| <b>PREPAREDNESS: Measures to ensure timely and effective responses from the healthcare system*</b> |  |   |   |  |   |  |            |
| <b>10</b>  | Business continuity plan - for 1 <sup>st</sup> and 2 <sup>nd</sup> line pharmacy staff |   |   |  |   |  |            |
| <b>11</b>  | Stock and supply of essential medicines (as defined in your country)                   |   |   |  |   |  |            |
| <b>12</b>  | Stock and supply of hand sanitizers  |   |   |  |   |  |            |
| <b>13</b>  | Stock and supply of protective masks   |   |   |  |   |  |            |



INSTITUTE  
FOR EVIDENCE  
BASED HEALTH

Advancing Knowledge  
Transforming Healthcare

## Pharmacy Services in Europe: Evaluating Trends and Value PART 2: PHARMACY INTERVENTIONS ON COVID-19

### COUNTRY ASSESSMENT

|   | PHARMACY INTERVENTIONS ON COVID-19  | Provided in most (≥80%) pharmacies (Y/N) | Expanded powers granted to pharmacists through amending regulations (Y/N)<br><i>If Y, please provide link or reference</i> | Remunerated by Government / Payer (Y/N)<br><i>If Y and available please provide fees and currency</i> | Extra legislation passed by pharmacy regulators in view of covid-19 (Y/N)<br><i>If Y, please provide link or reference</i> | Other data sources<br><i>Please provide links or references</i> | OBS |
|---|---|--|--|---|--|---|-----|
| 14  | Quantity limits for patient for the supply of individual medicines  |  |  |   |  |   |     |
| <b>RESPONSE: Immediate actions in response to COVID-19 pandemic*</b>      |   |  |  |   |  |   |     |
| 15  | Symptom-based referral pathways for suspected cases   |  |  |   |  |   |     |
| 16  | Point-of-care antigen test-based referral pathways for suspected cases  |  |  |   |  |   |     |
| 17  | Increased demand / changes to repeat dispensing (=prescription renewal of chronic medications)                |  |  |   |  |   |     |
| 18  | Emergency supply of medications (without prescription)  |  |  |   |  |   |     |
| 19  | Supply of those medicines, which are usually supplied in the hospital setting (e.g. oncology, antiretroviral) |  |  |   |  |   |     |
| 20  | Increased demand / changes to home delivery of medicines  |  |  |   |  |   |     |
| 21  | Hotline numbers for home delivery of medicines  |  |  |   |  |   |     |
| 22  | Dealing with the supply of medicines shortages  |  |  |   |  |   |     |
| 23  | Preparing alcohol-based hand sanitizer formulations   |  |  |   |  |   |     |
| 24  | Pharmacy telephone support to vulnerable patients during isolation / lockdown                                 |  |  |   |  |   |     |
| 25  | Hotline numbers / protocol for pharmacies for reporting on domestic violence during isolation / lockdown      |  |  |   |  |   |     |
| 26  | Temporary waived prescription copayments for vulnerable patients  |  |  |   |  |   |     |
| 27  | Drive thru pharmacy services (initiated or increased)   |  |  |   |  |   |     |
| <b>RECOVERY: Measures to return to "normal" activities post-pandemic*</b> |   |  |  |   |  |   |     |
| 28  | Reestablishing normal patient care services and stock levels  |  |  |   |  |   |     |
| 29  | Dealing with the new vulnerable patients due to pandemic  |  |  |   |  |   |     |



**INSTITUTE  
FOR EVIDENCE  
BASED HEALTH**

Advancing Knowledge  
Transforming Healthcare

## Pharmacy Services in Europe: Evaluating Trends and Value PART 2: PHARMACY INTERVENTIONS ON COVID-19

### COUNTRY ASSESSMENT

|           | <b>PHARMACY INTERVENTIONS ON COVID-19</b>  | <b>Provided in most (≥80%) pharmacies (Y/N)</b> | <b>Expanded powers granted to pharmacists through amending regulations (Y/N)</b><br><i>If Y, please provide link or reference</i> | <b>Remunerated by Government / Payer (Y/N)</b><br><i>If Y and available please provide fees and currency</i> | <b>Extra legislation passed by pharmacy regulators in view of covid-19 (Y/N)</b><br><i>If Y, please provide link or reference</i> | <b>Other data sources</b><br><i>Please provide links or references</i> | <b>OBS</b> |
|-----------|--|---|---|--|---|--|------------|
| <b>30</b> | Referral pathways of exposed patients to antibody testing for immunity assessment against COVID-19 |   |   |  |   |  |            |
| <b>31</b> | COVID-19 vaccination   |   |   |  |   |  |            |

- 32.** Were expanded powers granted to pharmacies to perform an already existing pharmacy service? Yes \_\_\_ Please explain \_\_\_\_\_ No \_\_\_
- 33.** Were there any new pharmacy services initiated at Government's request or by amending regulation in country? Yes \_\_\_ Please explain \_\_\_\_\_ No \_\_\_
- 34.** Were there any emergency temporary closures of pharmacies in country? Yes \_\_\_ How many pharmacies? \_\_\_ (\_\_\_ % on total) No \_\_\_
- 35.** Were there deaths of pharmacy staff due to COVID-19 in country? Yes \_\_\_ How many deaths? \_\_\_ No \_\_\_

**THANK YOU**

\* Classification and definition of pharmacy intervention categories on COVID-19 based on Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis. Res Soc Adm Pharm 2020; <https://doi.org/10.1016/j.sapharm.2020.03.015> .